IDH1 and myelodysplastic syndrome: FT-2102 is a small-molecule, oral allosteric inhibitor of mutant IDH1 (IC50 = 10 nM) currently undergoing a clinical study for the treatment of patients with IDH1-mut AML or higher-risk myelodysplastic syndrome, who relapsed or are refractory to a prior therapy or were disqualified for standard treatment.